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Statement of Translational Relevance  
Allogeneic nonmyeloablative hematopoietic stem cell transplant (NM-HSCT) can cure 
chemotherapy refractory chronic lymphocytic leukemia (CLL). A graft-versus-leukemia (GVL) 
effect is required for tumor eradication after NM-HSCT, but the mechanisms responsible are not 
well defined, and separating GVL from graft-versus-host disease (GVHD) is difficult. In a cohort 
of NM-HSCT recipients, we investigated whether CLL-reactive T cells could be detected 
post-transplant and correlated their presence with antitumor activity. T cells specific for CLL 
developed with variable kinetics in all patients who achieved a complete remission, but not in 
patients who failed to respond to NM-HSCT. CLL-reactive T cells were specific for recipient 
minor histocompatibility antigens expressed by CLL and other recipient cells, but also antigens 
that were only expressed by the malignant B cells. The molecular identification of minor 
histocompatibility and tumor-associated antigens expressed on CLL may define targets for 
adoptive T cell transfer or vaccination to augment GVL activity without GVHD. 
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Abstract  
Purpose: Allogeneic NM-HSCT can result in durable remission of chronic lymphocytic 
leukemia (CLL). It is thought that the efficacy of NM-HSCT is mediated by recognition of tumor 
cells by T cells in the donor stem cell graft. We evaluated the development of cytotoxic T 
lymphocytes (CTL) specific for CLL after NM-HSCT to determine if their presence correlated 
with antitumor efficacy.   
Experimental Design: Peripheral blood mononuclear cells obtained from twelve transplant 
recipients at intervals after NM-HSCT were stimulated in vitro with CLL cells. Polyclonal T cell 
lines and CD8+ T cell clones were derived from these cultures and evaluated for lysis of donor 
and recipient target cells including CLL. The presence and specificity of responses was 
correlated with clinical outcomes. 
Results: Eight of the 12 patients achieved remission or a major antitumor response and all eight 
developed CD8+ and CD4+ T cells specific for antigens expressed by CLL. A clonal analysis of 
the CD8+ T cell response identified T cells specific for multiple minor histocompatibility (H) 
antigens expressed on CLL in six of the responding patients. A significant fraction of the CD8+ T 
cell response in some patients was also directed against non-shared tumor-specific antigens. By 
contrast, CLL-reactive T cells were not detected in the four patients who had persistent CLL after 
NM-HSCT, despite the development of GVHD.  
Conclusions: The development of a diverse T cell response specific for minor H and 
tumor-associated antigens expressed by CLL predicts an effective GVL response after 
NM-HSCT. 
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Introduction 
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure many hematological 
malignancies, although graft-versus-host disease (GVHD) and relapse remain significant 
obstacles. The efficacy of HSCT results from cytotoxic conditioning and a graft-versus-leukemia 
(GVL) effect (1, 2). Myeloablative conditioning regimens that employ total body irradiation 
and/or intensive chemotherapy exhibit potent antitumor activity, but are limited to young patients 
due to nonhematopoietic toxicities. Allogeneic HSCT can be extended to older patients and those 
with comorbidities using reduced intensity nonmyeloablative conditioning regimens that provide 
less antitumor activity but immunosuppress the recipient sufficiently to allow engraftment of 
donor hematopoietic cells and enable a GVL effect (3-7). Nonmyeloablative HSCT (NM-HSCT) 
leads to remission in a subset of patients with refractory indolent hematologic malignancies 
including chronic lymphocytic leukemia (CLL) (8-17). The eradication of CLL after NM-HSCT 
is associated with GVHD, and presumed to be a consequence of T cell recognition of 
alloantigens expressed by leukemic cells (18). However, many patients do not respond to 
NM-HSCT despite developing GVHD and others respond without significant GVHD. Thus, the 
basis for a successful GVL effect remains poorly defined in individual patients.  
CLL is amenable to studies of the GVL effect because leukemia cells can be obtained 
from most patients, and induced to become efficient antigen presenting cells (APC) by 
stimulation through CD40 (19-21). Here, we used recipient CD40L stimulated CLL as APC to 
isolate donor T cells that were specific for CLL after NM-HSCT. CD8+ and CD4+ T cells that 
recognized multiple minor H antigens expressed on recipient CLL were isolated from all patients 
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who achieved or maintained a complete remission (CR) after NM-HSCT. In addition, CD8+ T 
cell clones that recognized recipient CLL but not EBV-transformed B cells were isolated from 
responding patients, suggesting a component of the response is directed against tumor-specific 
determinants. Despite the development of GVHD and high levels of donor T cell chimerism, 
CLL-specific T cells were not detected in recipients with persistent or progressive leukemia. 
These results demonstrate that the specificities of the T cell responses that develop after 
allogeneic NM-HSCT are critical in determining antitumor efficacy, and illustrate the potential to 
manipulate T cell reactivity to target antigens expressed selectively by tumor cells to improve 
outcome. 
 
Materials and Methods 
Patient and Donor Eligibility 
Patients with CLL who failed to meet National Cancer Institute (NCI) Working Group 
Criteria for complete or partial response (22) after therapy with a regimen containing fludarabine, 
or who relapsed within 12 months after completing fludarabine, and had an HLA-A, -B, -C, 
-DRB1, and –DQB1 matched related or unrelated donor were eligible. Exclusion criteria 
included central nervous system involvement, history of malignancy other than CLL within the 
past 5 years, Karnofsky score less than 60%, and severe cardiovascular, pulmonary, or hepatic 
dysfunction. Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood was the 
source of stem cells. All patients and their related donors signed consent forms approved by the 
FHCRC institutional review board. Informed consent was obtained from the unrelated donors 
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according to National Marrow Donor Program (NMDP) regulations. 
 
Treatment Plan 
Patients were conditioned for transplantation with fludarabine 30 mg/m2/day on days –4 
to –2, and 200 cGy of total body irradiation on day 0. The patients received immunosuppression 
with cyclosporine or tacrolimus given orally every 12 hours beginning on day -3; and 
mycophenolate mofetil given beginning on day 0 every 12 hours to recipients with related donors, 
and every 8 hours to recipients with unrelated donors (16). Analysis of donor/recipient 
chimerism in peripheral blood CD3+ and CD33+ cells was performed post-transplant on 
approximately day 28, 56, and 84; at 6, 12, 18 months; and then annually.  
 
Disease Response and GVHD Assessment 
Disease response was assessed using NCI Working Group Criteria (22). Patients 
underwent evaluation for minimal residual CLL by flow cytometry of peripheral blood and bone 
marrow. Diagnosis and grading of acute and chronic GVHD were performed according to 
established criteria (23, 24). 
 
Cell Lines 
Epstein-Barr virus transformed B-cells (B-LCL) were generated from patients and donors 
as described (25). B-LCL and CLL from individuals of known HLA types were used as targets to 
determine the HLA-restricting allele and the frequency of individual minor H or 
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tumor-associated antigens. Fibroblast cell lines were generated and maintained as described (25). 
 
Isolation of CLL-Reactive T Cell Lines and Clones 
PBMC were isolated by centrifugation over Ficoll-Hypaque and cryopreserved. NIH 3T3 
cells transfected with human CD40L (tCD40L) were a gift of Dr. J. Schultze and used to 
generate CD40 activated CLL cells (CD40-CLL) as described (26). After 3 days of activation, an 
aliquot of cells was analyzed for expression of CD5, CD19, HLA-class I, HLA-class II, CD80, 
CD86, CD54 and CD58 to determine purity and confirm activation through CD40. A second 
aliquot of CD40-CLL was γ-irradiated and used as APC to stimulate post-transplant PBMC. 
When further expansion of CLL cells was required, CD40-CLL were transferred to fresh tCD40L 
every 3-4 days. 
To generate T cell lines, PBMC (3x106/well) obtained from the recipient at intervals 
post-transplant were stimulated with γ-irradiated (35 Gy) recipient CD40-CLL (0.75 x106/well) 
in RPMI, 10% human serum, 2 mM L-glutamine and 1% penicillin-streptomycin. Cultures were 
restimulated after seven days with γ-irradiated recipient CD40-CLL at a responder to stimulator 
ratio of 4:1. The medium was supplemented with IL-7 (10 ng/mL on day 0 of each stimulation) 
and IL-2 (2 U/mL) on day 3 after the first stimulation, and then 10 U/mL on days 1 and 4 of the 
second stimulation. After 2 weeks, T cell lines were tested for cytotoxic activity against 
recipient- and donor-derived B-LCL and recipient CD40-CLL. 
CD8+ and CD4+ T cells that secreted IFN-γ after stimulation with CD40-CLL were 
sort-purified using IFN-γ capture. An aliquot (1x106 cells) of each of the T cell lines was 
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co-cultured with CD40-CLL (1-2 x 106) in media containing 20 U/ml IL-2 at 37℃ for 4 hours 
and then processed as described (27, 28). CD4+ and CD8+ IFN-γ+ cells were sorted and then 
expanded by stimulation with anti-CD3 monoclonal antibody or cloned at 0.5 cells/well in 
96-well round bottom plates with anti-CD3 monoclonal antibody (30 ng/ml) as described (25, 
29). In selected cases γ-irradiated recipient CD40-CLL (2x103 cells/well) were used for 
stimulation in cloning cultures in place of anti-CD3 monoclonal antibody. After 12-14 days, 
cloning wells with growth were tested for cytotoxicity against recipient and donor B-LCL to 
identify T cell clones specific for recipient minor H antigens. In selected cases, recipient CLL 
cells were included as target cells during screening to identify T cell clones specific for putative 
tumor-associated antigens expressed by CLL but not nonmalignant B cells. 
 
Cytotoxicity Assays and ELISA  
Target cells, which included B-LCL, CD40-CLL, primary CLL, and fibroblasts, were 
labeled with 51Cr for 2 hours, washed twice, plated in triplicate at 1-2 x 103 cells/well with 
effector cells at various effector to target (E/T) ratios. When less than 75% of the recipient 
PBMC activated with CD40 expressed CD5 and CD19, the CD5+ CD19+ cells were sorted using 
a FACSVantage cell sorter (Becton Dickinson) prior to cytotoxicity assays. Fibroblasts were 
treated with 100 U/ml IFN-γ for 48 hours before use as targets. In some experiments, 
Cr51-labeled target cells were pulsed with peptides (10 μg/ml) for 30 minutes, and then washed 
prior to use in the assay. Supernatants were harvested for γ-counting after a 4-hour incubation of 
effector and target cells, and specific lysis calculated using the standard formula. 
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For IFN-γ ELISA, target and effector cells were washed twice and plated in triplicate at 
an E/T ratio of 3:1. After a 24 hour incubation, the supernatant was collected and analyzed for 
IFN-γ using a primary and a biotinylated secondary anti human IFN-γ antibody (Pierce 
Biotechnologies, Rockford, IL) according to the manufacturer’s instructions. Color development 
was performed with streptavidin-conjugated HRP and TMP (Sigma-Aldrich, St. Louis, MO), and 
optical density determined using a Thermo Multiskan EX reader (Thermo Scientific, Waltham, 
MA). A standard curve was obtained with serial dilutions of recombinant human IFN-γ with a 
potency of 2.0 x 104 IU/μg (R&D Systems, Minneapolis, MN).  
 
Flow cytometry 
T cells, primary CLL and CD40-CLL were stained with one or more of the following 
monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE): 
CD3, CD4, CD5, CD8, CD19, CD40, CD54, CD58, CD80, CD86, HLA-class I, HLA-DR and 
isotype matched control antibodies (BD Pharmingen). Flow cytometric analysis was performed 
on a FACSCalibur, and data were analyzed using CellQuest software (Becton Dickinson). 
 
Results 
Patient characteristics and clinical outcomes after allogeneic NM-HSCT.  
The characteristics of twelve patients treated with NM-HSCT from HLA matched donors 
are shown in Table 1. Eleven of the twelve patients had >50% bone marrow involvement with 
CLL at the time of NM-HSCT, and one patient (UPN 18802) was transplanted in CR after 
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receiving chemotherapy for Richter’s transformation. Seven of the 12 patients achieved or 
maintained a CR three to twelve months after transplant. One of these seven patients (UPN 9661) 
only achieved a CR after receiving a donor leukocyte infusion (DLI) for the treatment of 
Epstein-Barr virus associated lymphoproliferative disease. One additional patient (UPN 29449) 
has an ongoing partial remission (PR) with a reduction in bone marrow tumor burden from 70% 
pre transplant to 5% at six months after transplant. Six of these eight patients with a major 
antitumor response developed acute GVHD and five developed extensive chronic GVHD. Four 
patients had persistent or progressive CLL after NM-HSCT, despite the administration of DLI to 
one of these patients (UPN 28196). All four non-responding patients developed acute GVHD, 
and one of three that survived beyond day 100 developed chronic GVHD. One of the 
non-responding patients remains alive with persistent CLL. There was no difference in the 
immunosuppressive therapy regimens used for GVHD prophylaxis between responding and 
non-responding patients. 
 
Generation of CLL-reactive T cells from post-transplant PBMC 
We hypothesized that donor cell engraftment might result in the development of a T cell 
response specific for recipient minor H or tumor-associated antigens on CLL and contribute to 
tumor regression. Aliquots of recipient CLL that were cryopreserved pre-transplant were used to 
stimulate T cells obtained from the recipient post-transplant after donor engraftment was 
established. CLL expresses class I and II MHC molecules and can be recognized by CD8+ and 
CD4+ T cells, but has low levels of costimulatory and adhesion molecules (19, 20). Engagement 
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of CD40 on CLL with CD40 ligand (CD40L) upregulates the expression of co-stimulatory 
(CD80 and CD86), adhesion (CD54 and CD58) and MHC molecules and makes the tumor cells 
more efficient APC (19, 20, 26). Therefore, we co-cultured the pre-transplant CLL from the 
eleven patients with a high tumor burden with tCD40L prior to their use in vitro for stimulating 
post-transplant T cells. The frequency of CLL cells in the cultures after CD40L activation was 
30.1-97.4% (median 80%) as assessed by co-expression of CD5 and CD19. In the patient in 
morphologic CR prior to HSCT, we expanded CD5+ CD19+ CLL cells from bone marrow cells 
after multiple stimulations with tCD40L and used these cells as APC. CLL activated through 
CD40 expressed higher levels of co-stimulatory, adhesion, and MHC molecules as previously 
reported (data not shown) (19, 20, 26). 
PBMC were obtained from each recipient at intervals after HSCT, stimulated twice one 
week apart with γ-irradiated recipient CD40-CLL, and then evaluated for lysis of recipient 
CD40-CLL, and recipient and donor B-LCL. CD40-CLL rather than thawed primary CLL cells 
were used as target cells in these experiments because CD40-CLL were of higher purity and 
exhibited improved viability and uptake of 51Cr. Cytotoxic T lymphocytes (CTL) that recognized 
both recipient CLL and B-LCL, but not donor B-LCL were detected after two stimulations at one 
or more time points from all seven patients with a CR after HSCT or DLI, and from the one 
patient with a major partial response at six months after HSCT (Figure 1A). Stimulation of 
PBMC obtained directly from each of the donors with recipient CD40-CLL under the same 
conditions did not elicit specific CTL activity against recipient CLL or B-LCL (data not shown), 
demonstrating the reactivity detected in post-transplant PBMC resulted from in vivo activation of 
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T cells to recipient minor H and possibly tumor-associated antigens.  
The antitumor activity of NM-HSCT is often delayed for several months after transplant 
and we found the kinetics with which CLL-reactive T cell responses developed after HSCT 
differed in individual patients. CLL-reactive T cells developed rapidly after transplant in some 
patients including UPN 22388 (Figure 1A), who had a circulating lymphocyte count of 28,500 
cells/μl consisting of >90% CD5+ CD19+ tumor cells at the time of transplant. CLL-reactive T 
cells were detected in this patient in the PBMC sample obtained on day 35 post-transplant, and 
coincided with a dramatic reduction in CD19+ CD5+ B cells. T cell responses specific for CLL 
were not detected in other patients until several months after transplant, after improvement in 
donor CD3 T cell chimerism to >90% (UPN 24487; UPN 25843) or reduction in 
immunosuppressive drug therapy (UPN 21899) (Figure 1A). All four of the patients who did not 
achieve CR after transplantation lacked specific cytotoxicity for recipient CLL at any of the time 
points analyzed (Figure 1B), despite the occurrence of GVHD in all patients and >90% donor 
CD3 T cell chimerism in three of the four patients.  
The development of GVHD in the non-responding patients indicates that alloreactive T 
cells must be present in these patients, but our assays suggest the alloreactivity was not directed 
against antigens on malignant cells. An alternative explanation is that there was a defect in APC 
function of the CLL cells from the nonresponding patients. To address this possibility, we 
evaluated the ability of CD40-CLL from the four non-responding patients and one responding 
patient to elicit alloreactive T cells in a mixed lymphocyte culture using T cells from an MHC 
disparate unrelated donor. We found that the CLL from the non-responding patients were 
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equivalently effective APC (Figure 2A, B). Additionally, a non-responding patient (UPN 28196) 
and a responding patient (UPN 22388) were both HLA-A2+ males, and the CLL from each of 
these patients stimulated IFN-γ production from a T cell clone specific for the SMCY minor H 
antigen (FIDSYICQV) (Figure 2C). These data demonstrate the failure to detect CLL-reactive T 
cells in non-responders was not due to lack of APC function by the tumor cells, but rather 
suggest that the specificity of donor alloreactive T cells that caused GVHD in the recipient was 
not directed against minor H antigens expressed on recipient CLL. 
 
CD4+ and CD8+ T cells that recognize CLL develop in responding patients 
Analysis of the phenotype of the CLL-reactive T cell lines generated from each of the 
eight responding patients showed the presence of both CD4+ and CD8+ T cells in cultures from 
all of the 8 patients. To determine whether both T cell subsets recognized CLL, we stimulated an 
aliquot of the polyclonal cultures derived from each patient with recipient CD40-CLL, and 
evaluated IFN-γ production. As shown for two representative patients, a fraction of the CD4+ and 
CD8+ T cells from each patient produced IFN-γ after stimulation with recipient CLL and B-LCL, 
but not with donor B-LCL, demonstrating recipient minor H antigens on CLL were recognized 
by both CD4+ and CD8+ T cells (Figure 3A, B). To determine whether both CD4+ and CD8+ T 
cells also lysed CLL, we sorted T cells that produced IFN-γ from two patients into CD4+ and 
CD8+ fractions and expanded each subset by stimulation with anti-CD3 monoclonal antibody. 
After a single cycle of expansion, the CD4+ IFN-γ+ fraction contained 96.2 and 99.8% CD4+ T 
cells respectively, and the CD8+ IFN-γ+ fraction contained 74.1% and 96.2% CD8+ T cells 
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respectively (data not shown). We used these enriched populations as effector cells against 
recipient CD40-CLL, primary CLL, and recipient and donor B-LCL. The CD4+ T cells from 
each patient exhibited absent or weak lytic activity against recipient CD40-CLL and B-LCL, and 
failed to lyse primary CLL cells (Figure 3C). By contrast, the CD8+ T cells from each patient 
efficiently lysed both recipient CD40-stimulated and primary CLL (Figure 3D), and lysis was 
inhibited by anti class I monoclonal antibody (data not shown). Donor B-LCL and CD40 
activated B cells served as controls and were not lysed by CD8+ T cells.  
 
Clonal analysis of the CD8+ T cell response to CLL reveals recognition of both minor 
histocompatibility and tumor-associated antigens.  
All of the patients who responded to NM-HSCT also developed GVHD, which is 
mediated by donor T cells specific for minor H antigens expressed on cells in the skin, 
gastrointestinal tract, and/or liver (30-32). Minor H antigens have previously been identified that 
are preferentially expressed on hematopoietic cells including B-lineage cells, and recognition of 
these antigens may be associated with less GVHD (30, 33-35). Thus, the isolation of T cell 
clones from CLL-reactive T cell lines derived from our patients would provide reagents to 
identify additional minor H antigens that could potentially be targeted to induce a GVL response 
without GVHD. We focused our efforts on analysis of the CD8+ T cell response because the 
development of minor H antigen-specific CD8+ T cells after DLI has correlated with tumor 
regression in other settings (33, 36), and CD8+ T cells that produced IFN-γ in response to 
CD40-CLL lysed primary CLL cells more efficiently than CD4+ T cells (Figure 3C, D).  
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We derived CD8+ T cell clones from T cell lines generated at time points that coincided 
with tumor regression from 7 responding patients. In three patients where adequate numbers of 
cryopreserved CLL was available, γ-irradiated CLL rather than anti-CD3 monoclonal antibody 
was used for stimulation in the cloning cultures. In the four patients where tumor cells were 
limited, cloning wells positive for growth were screened for recognition of recipient and donor 
B-LCL to identify clones specific for minor H antigens. These T cell clones were subsequently 
analyzed for recognition of recipient CD40-CLL and fibroblasts to identify minor H antigens that 
were expressed on tumor cells and preferentially on hematopoietic cells. In the three patients 
where we had sufficient tumor cells for cloning, we tested each positive well for recognition of 
recipient CLL and recipient and donor B-LCL to identify T cell clones specific for either minor 
H or tumor-associated antigens.  
Multiple CD8+ T cell clones that recognized a minor H antigen presented by both 
recipient CD40 CLL and B-LCL, but not donor B-LCL were isolated from all 7 patients (11 for 
UPN 22388; 10 for UPN 9661; 6 for UPN 21899; 2 for UPN 24487; 12 for UPN 18802; 6 for 
UPN 28736; 13 for UPN 29449). We attempted to map the HLA-restricting allele for each minor 
H antigen-specific T cell clone by testing recognition of a panel of B-LCL from unrelated donors 
that shared only a single HLA allele with the recipient. The restricting HLA allele and an 
estimate of the allele frequency was determined for 9 minor H antigen-specific T cell clones 
(Table 2A). Three of these T cell clones also lysed IFN-γ pre-treated fibroblasts (>10% lysis) 
demonstrating the expression of the minor H antigen recognized by these T cells was not 
restricted to hematopoietic cells. Five clones did not lyse fibroblasts and were specific for minor 
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H antigens that are potentially selectively expressed on hematopoietic cells (Table 2A). We were 
unable to map the restricting HLA-allele for many of the T cell clones because the panel of 
partially matched unrelated B-LCL was not sufficient for conclusive assignment. However, based 
on differential recognition of B-LCL from unrelated donors, we could conclude that the T cell 
lines from 6 of the 7 patients targeted at least two distinct minor H antigens. Thus, at the time of 
tumor regression after NM-HSCT, the T cell response was directed against multiple distinct 
minor H antigens expressed on CLL. 
UPN 22388 had a dramatic reduction in circulating tumor cells early after transplant and 
did not develop GVHD in the first 80 days (Figure 4A). Eleven T cell clones were isolated from 
blood obtained on day 63 and all were restricted by HLA-B40 as shown for clone 2A2 (Table 
2A). These T cell clones did not recognize dermal fibroblasts consistent with the absence of 
clinical GVHD in this patient at day 63 after HSCT. The patient subsequently developed 
persistent chronic GVHD at day 120 suggesting that the T cell response might have broadened to 
include recognition of additional minor H antigens. T cell clones were generated from blood 
obtained at day 120 and 730 after transplant when the patient had active chronic GVHD, and 
analysis of the HLA-restricting allele for 9 of these T cell clones revealed recognition of 
additional distinct minor H antigens presented by HLA-A2, HLA-A31, HLA-B15, HLA-B40 and 
HLA-Cw3 (Table 2B). In contrast to the HLA-B40-restricted T cell clone isolated at day 63 that 
did not recognize fibroblasts, the minor H antigens targeted by 5 of the T cell clones isolated at 
these later time points were expressed both by CD40 CLL and fibroblasts. One clone (13C6) 
isolated at day 120 only lysed B-LCL from male HLA-A2+ donors suggesting it was specific for 
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a minor H antigen encoded on the Y-chromosome. Further studies revealed that 13C6 recognized 
a previously described epitope encoded by the SMCY gene (Figure 4B, C), that has been 
associated with GVHD in prior studies (30). Of interest, SMCY-specific T cells were not 
detected in the T cell lines generated at day 63 by tetramer analysis when the patient did not have 
GVHD, but tetramer binding cells were readily detected in the T cell lines generated from day 
120 and 374 samples (Figure 4D). These data demonstrate that additional minor H 
antigen-specific T cells are recruited with time after NM-HSCT, analogous to epitope spreading 
that has been described in autoimmunity and potentially induced by cytotoxic tumor cell death 
(37, 38). The T cell clones that were specific for broadly expressed minor H antigens and isolated 
late after NM-HSCT, also recognized the recipient’s CLL, and may contribute to sustaining the 
GVL effect (Table 2B). 
 The percentage of CD8+ T cells that produced INF-γ was higher after stimulation with 
CD40-CLL compared to recipient B-LCL in many patients, suggesting that T cells specific for 
minor H antigens or tumor-associated antigens that are selectively expressed on CLL may be 
present. In 3 patients in which sufficient tumor cells were available to use both as stimulator cells 
during cloning and as target cells in screening assays, multiple T cell clones that recognized 
recipient CLL cells but not B-LCL were identified (Table 2C). The proportion of T cell clones 
that lysed recipient CLL but not B-LCL varied between 30 and 79% of all T cell clones isolated 
from these patients, suggesting that the tumor-specific response was a significant component of 
the overall T cell response to CLL. We tested 16 clones obtained from the 3 patients against 
panels of primary and activated CLL from other patients sharing at least one HLA-allele to 
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determine if these T cell clones might be directed against shared and/or non-shared 
tumor-associated antigens. Twelve of the 16 clones only lysed primary and/or activated CLL 
from the particular patient they were derived, but not CLL from other patients. Four clones 
generated from UPN 22388 (14D1, 8A9, 10A10, 30B2) recognized CLL from one or more 
unrelated patients, however we did not have large enough panels of CLL to conclusively identify 
the HLA-restricting allele (data not shown). Nevertheless, our data demonstrate that T cells 
specific for antigens exclusively expressed on CLL but not on B-LCL are elicited after 
NM-HSCT. These antigens may include non-shared or shared tumor-specific antigens on CLL 
cells and/or minor H antigens that are only expressed on CLL.   
 
Discussion 
NM-HSCT can result in a durable remission for 40-70% of CLL patients who progress 
after fludarabine based regimens (11, 15-17). The efficacy of HSCT in CLL does not correlate 
with factors that determine outcome after standard chemotherapy and is ascribed to a GVL effect 
mediated by immune cells in the stem cell graft (9, 10, 13, 14). This study is the first to analyze 
the presence and kinetics of development of CLL-reactive T cells after NM-HSCT and to 
correlate T cell responses with antitumor efficacy. The results demonstrate that T cells that 
specifically recognize recipient CLL and B-LCL, but not donor B-LCL develop in all patients 
who achieved or maintained an antitumor response after NM-HSCT, but not in patients with 
persistent or progressive disease.  
We used recipient CD40-CLL rather than PBMC as APC since our focus was to uncover 
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T cells specific for antigens on the tumor cells, and the number of T cells in post-transplant 
samples was not sufficient to compare the alloreactivity that would be elicited using recipient 
APC derived from different cell types. In all responding patients both CD8+ and CD4+ T cells 
that recognized recipient CLL and B-LCL, but not donor B-LCL were detected by IFN-γ 
production and/or cytotoxicity demonstrating that a component of the T cell response that 
developed in responding patients is directed against minor H antigens on CLL. We used 
CD40-CLL cells as target cells in the initial assays to assess tumor cell recognition by the 
polyclonal T cell lines generated from each patient. In subsequent experiments, CD4+ and CD8+ 
T cells were selectively enriched from the T cell lines and assessed for recognition of primary 
CLL cells. CD8+ T cells efficiently lysed primary CLL cells demonstrating that tumor cell 
recognition by this subset did not depend on CD40 activation. Isolation of individual CD8+ T cell 
clones from the polyclonal T cell lines confirmed that a significant component of the antitumor 
response was specific for minor H antigens, some of which were not broadly expressed on 
nonhematopoietic cells. Studies are in progress to clone the genes that encode minor H antigens 
recognized by these CLL-reactive CD8+ T cells.  
A greater frequency of T cells produced IFN-γ in response to recipient CLL than to 
recipient B-LCL, suggesting that nonpolymorphic tumor-associated antigens expressed only by 
CLL may be recognized. This was confirmed in a subset of three patients where sufficient tumor 
cells were available to use as APC in the cloning cultures. CD8+ T cell clones that lysed recipient 
CLL but not B-LCL were isolated from all three patients. The tumor-associated antigens 
recognized by most of the T cell clones were not shared by CLL cells from unrelated individuals, 
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suggesting these antigens are derived from mutations or protein sequences that are unique to the 
CLL of the individual patient. Autologous CLL-reactive T-cells have been described previously 
(39), and immunoglobulin idiotype has been identified as a tumor antigen in B cell malignancies 
(40, 41). The possibility that idiotype is being recognized by a component of the T cell response 
elicited after NM-HSCT is being currently being investigated. 
The results of our analysis of CLL-reactive T cells after NM-HSCT provide insight into 
why the GVL effect may be so potent in eradication of this malignancy. Efforts to target 
malignancies by T cell immunotherapy are commonly directed at a single tumor-associated 
antigen, and can fail because of the outgrowth of antigen loss tumor variants (42, 43). Our 
studies show that the CLL-reactive T cell response after allogeneic NM-HSCT is comprised of 
both CD8+ and CD4+ T cells, and commonly directed against multiple antigens. Moreover, 
analysis of the CD8+ T cell response over time in a single patient illustrated the emergence of 
new T cell clones specific for minor H antigens expressed by CLL. This diversification of the 
alloreactive T cell response capable of recognizing CLL may diminish the potential for 
outgrowth of tumor cell variants, and may explain why complete tumor regression is often 
delayed for several months.  
Stimulation of post-transplant PBMC with recipient CD40-CLL did not elicit 
CLL-reactive T cells from any patient with persistent or progressive disease after transplant, 
despite GVHD in these patients. The failure of the GVL effect in these patients may be due to the 
absence of disparity between donors and recipients in the subset of minor H antigens that are 
expressed by CLL, or to a failure of T cells specific for disparate minor H antigens expressed on 
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CLL to be activated and expand in vivo. CLL cells have been demonstrated to induce defects in 
T cells in tumor bearing patients and to be defective in immune synapse formation (44, 45), and 
it is possible that a large tumor burden at the time of transplant reduces the activation of donor T 
cells specific for antigens present on CLL.   
Acute or chronic GVHD developed in all of the patients who achieved a CR, 
emphasizing the difficulty separating the potent GVL effect from GVHD with current 
approaches to NM-HSCT. Clonal analysis of CLL-reactive CD8+ T cells that developed in 
patients with GVHD demonstrated recognition of minor H antigens that are broadly expressed on 
nonhematopoietic tissues (30, 32). Prior studies have identified minor H antigens such as 
PANE-1 and HB-1 that are selectively expressed on B-lineage cells (34, 35), but the allele 
frequency of these antigens is such that very few patients could benefit from targeted therapy to 
induce a GVL effect. Discovery of additional determinants with selective expression on recipient 
hematopoietic cells may allow targeting of leukemic cells by adoptive T cell transfer or 
vaccination. Ideally, nonpolymorphic antigens expressed on CLL might be used as targets for 
immunotherapy. There is evidence that immunoglobulin framework, survivin, and fibromodulin 
peptides can be presented by CLL (46-48). Further studies to identify tumor-specific and minor 
H antigens that are recognized by T cells that develop after NM-HSCT might lead to more 
effective and selective targeting of malignant cells after NM-HSCT. 
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Titles and legends to figures 
Figure 1. Cytotoxicity of T cell lines generated from NM-HSCT recipients by stimulation 
with recipient CD40-CLL. PBMC were obtained from recipients at the designated days after 
NM-HSCT, stimulated twice one week apart with γ-irradiated recipient CD40-CLL, and tested in 
a cytotoxicity assay against Cr51-labeled recipient CD40-CLL (■), recipient B-LCL (■) and 
donor B-LCL (□). Data is shown for an effector to target ratio of 30:1 or 40:1. A. Reactivity of 
T cell lines generated from patients who had a major antitumor response after NM-HSCT. B. 
Reactivity of T cell lines generated from patients who had persistent or progressive disease after 
NM-HSCT.  
Figure 2. CD40-CLL from patients who fail to respond to nonmyeloablative HSCT are 
effective antigen presenting cells. A-B. PBMC from an unrelated HLA disparate individual 
(JKW) were stimulated in a mixed lymphocyte culture twice one week apart with γ-irradiated 
CD40-CLL derived from a responding patient (UPN 22388) as a control (A), and with 
γ-irradiated CD40-CLL from each of the 4 transplant recipients who failed to achieve a CR after 
transplant (B). The T cell lines were then assayed for cytotoxic activity against autologous 
(JKW) B-LCL, recipient CD40-CLL and recipient B-LCL if available at effector to target ratios 
of 1:1 – 100:1. C. CLL cells and B-LCL from an HLA-A2+ male patients who had progressive 
CLL after NM-HSCT (28196) or who responded to NM-HSCT (22388) were tested for the 
ability to stimulate an SCMY-specific T cell clone (CTL) to produce IFN-γ. T cells and 
stimulator cells were co-cultured at a ratio of 3:1 for 24 hours, supernatants were collected and 
IFN-γ was measured by ELISA.  
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Figure 3. CLL-reactive CD4+ and CD8+ T cells that produce IFN-γ and cytolytic CD8+ T 
cells are elicited after NM-HSCT in responding patients. A, B. T cell lines from two 
representative patients (UPN 22388 and UPN 9661) were stimulated with recipient CD40-CLL 
(top panels) and B-LCL (middle panels), and with donor B-LCL (lower panels) and stained with 
PE-conjugated IFN-γ detection reagent and either FITC-conjugated anti-CD4 or anti-CD8 
monoclonal antibodies. C, D. CD4+ and CD8+ T cells were isolated by IFN-γ+ capture after 
stimulation with recipient CD40-CLL, expanded with anti-CD3 monoclonal antibody and tested 
for lysis of recipient B-LCL, CD40-CLL and primary CLL cells, and against donor B-LCL and 
CD40 activated B cells. Data is shown at an effector to target ratio of 30:1.  
 
Figure 4. CD8+ T cells reactive with the SMCY peptide FIDSYICQV develop late after 
NM-HSCT in UPN 22388. A. Decline in total lymphocyte count in UPN 22388 in the first 28 
days post-transplant. B. Recognition of HLA-A*0201 LCL from unrelated female and male 
donors by CD8+ T cell clone 13C6 isolated from PBMC obtained at day 120 after allogeneic 
NM-HSCT. The data is shown for an E/T of 10:1. C. Recognition by SMCY-specific clone 13C6: 
recipient B-LCL ( ♦ ); donor B-LCL either unpulsed (■) or pulsed (  ) with 10 μM 
FIDSYICQV and 3 μg/ml human β-2 microglobulin. D. SMCY-specific T cells developed late 
after transplant in UPN 22388. The T cell lines generated from UPN 22388 at day +63, +120, 
and +374 after transplant and the T cell clone 13C6 were stained with PE-conjugated anti CD3 
and FITC conjugated anti CD8 monoclonal antibodies and an APC conjugated HLA-A*0201 
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Table 1 
Table 1 Characteristics and clinical outcome of recipients
UPN Age Sex (R/D) Donor Acute GVHD Chronic GVHD BM % CLL (Pre) Disease Response Outcome
22388 59 M/F MRD None E (skin, oral, GI) 80 CR at 12 mo. Alive, 47 months
9661 55 F/F MUD Grade II (skin) E (skin, eye, oral, liver) >90 CR at 7 mo. Dead, GVHD (day 1309)
21899 55 F/F MRD Grade II (skin) E (skin, oral, GI) 50 CR at 6 mo. Alive, 29 months
24487 45 M/F MRD None E (liver, GI) 50 CR at 12 mo. Alive, 12 months
23134 54 M/M MRD Grade II (GI) None 79 Progressive Dead, CLL (day 114)
19765 64 M/F MRD Grade III (skin, GI) E (skin, oral, eye) 90 Progressive Alive, >24 months
19647 62 M/F MUD Grade II (skin) NE >90 Persistent CLL Dead, Sepsis and pneumonia (day 60)
28196 64 M/F MRD Grade I (skin) None 92 Progressive Dead, CLL (day 214)
18802 64 M/M MUD Grade II (GI) Late acute GVHD (GI) 0 CR pre-transplant Dead, GVHD (day 227)
25843 55 M/M MRD Grade II (GI) None 50 CR Alive, 12 months
28736 57 M/M MRD Grade II (skin) None 55 CR at 3 mo. Dead, Aspergillus (day 120)
29449 58 M/M MUD Grade II (skin, GI) None 70 Partial Response Alive, 6 months
R = recipient; D = donor; M = male, F = female; MRD = matched related donor; MUD = matched unrelated donor;  GVHD = graft-versus-host disease; 
E = extensive; NE = not evaluated; CR = complete remission
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Table 2  
 
Table 2
A.  Characteristics of CD8+ T cell clones isolated from responding patients at the time of tumor regression
Days after HLA restricting Population
UPN A B C HCT T cell clone allele frequency R-B-LCL R-CD40 CLL D-B-LCL Fibroblast
9661 2 / 2 18 / 44 5 / 7 d+229 4F12 B44 2/12 (17%) 29 50 1 10
16B9 B44 6/12 (50%) 31 38 -1 4
20A5 A2 8/31 (26%) 37 43 2 4
21899 2 /24 8 / 18 7 / 12 d+355 2C2 B8 2/12 (17%) 46 39 10 7
24487 2 / 33 7 / 15 3 / 7 d+404 2B10 A2 8/27 (30%) 63 20 2 20
28736 1 / 3 7 / 8 7 / 7 d+110 9H11 A3 9/11 (81%) 42 71 -4 12
12C2 B7 6/11 (54%) 14 69 0 3
29449 1 / 3 7 / 13 6 / 7 d+80 2A11 A3 4/9 (44%) 56 35 0 ND
22388 2 / 31 15 / 40 3 / 3 d+63 2A2 B40 9/14 (64%) 73 64 -1 -1
22388 2 / 31 15 / 40 3 / 3 d+120 3C12 B40 10/14 (71%) 45 60 3 15
6F1 Cw3 6/13 (46%) 68 25 1 28
6F6 A31 2/4 (50%) 63 55 1 ND
13C6 A2 12/21 (57%) 63 60 1 25
16C4 B15 7/11 (63%) 70 65 0 22
14H10 A31 3/4 (75%) 14 71 0 ND
20G2 A31 3/4 (75%) 35 38 0 ND
d+730 5F4 B40 7/11 (63%) 79 72 0 71
7B8 A2 2/11 (18%) 67 80 0 ND
C.  Characteristics of T cell clones that only recognized patient CLL but not B-LCL
Days after
UPN A B C HCT T cell clone R-B-LCL R-CD40 CLL D-B-LCL
28736 1 / 3 7 / 8 7 / 7 d+110 2A3 1 66 1
8A9 0 55 0
9C9 0 34 0
12D6 2 53 0
29449 1 / 3 7 / 13 6 / 7 d+80 1A2 0 47 0
1B2 0 32 -1
2D2 -1 30 0
2E10 0 32 0
3G1 -1 54 -1
22388 2 / 31 15 / 40 3 / 3 d+120 14D1 0 40 0
17C5 0 58 0
18E5 0 61 0
d+730 8A9 0 42 0
10A10 0 60 0
23H3 0 78 0
30B2 0 76 0
HLA % Specific Lysis
HLA % Specific Lysis
B.  Characteristics of T cell clones isolated from UPN 22388 when the patient had clinical GVHD
